← Back to Drug List

AMIKACIN SUSP,INHL

Clinical Criteria Summary

Exclusion Criteria

  • Indication other than refractory Mycobacterium avium (MAC) pulmonary disease

Inclusion Criteria

  • Prescriber is an Infectious Diseases or Pulmonary Specialist
  • Patient has been treated with at least 6 months of guideline-based therapy without converting sputum cultures to negative (≥6-month final cultures remain positive)
  • Patient has failed or is intolerant of parenteral aminoglycoside therapy or is not a candidate for such therapy

Discontinuation Criteria

  • If the patient does not convert sputum cultures to negative with 6 months of ALIS + guideline-based therapy for refractory disease (≥6 month final culture results), therapy should be discontinued

Source Documents